Viewing Study NCT02201992

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:32 PM
Ignite Modification Date: 2026-02-20 @ 6:25 PM
Study NCT ID: NCT02201992
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-19
First Post: 2014-07-21
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Sponsor: ECOG-ACRIN Cancer Research Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None ALK Gene Rearrangement View
None ALK Gene Translocation View
None ALK Positive View
None Stage IB Non-Small Cell Lung Carcinoma AJCC v7 View
None Stage II Non-Small Cell Lung Cancer AJCC v7 View
None Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 View
None Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 View
None Stage IIIA Non-Small Cell Lung Cancer AJCC v7 View
Keywords: